Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Wednesday, March 21, 2018 at 9:10 a.m. ET / 6:10 a.m. PT. The conference will be held from March 20-21, 2018 in New York City. A live audio webcast of the presentation will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com, with an archived replay available for 30 days following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathway
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]Yahoo! Finance
- Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLGlobeNewswire
- Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Kura Oncology to Participate in Stifel Targeted Oncology Forum [Yahoo! Finance]Yahoo! Finance
KURA
Earnings
- 2/27/24 - Beat
KURA
Sec Filings
- 4/18/24 - Form ARS
- 4/12/24 - Form DEF
- 4/12/24 - Form DEFA14A
- KURA's page on the SEC website